

# Zhao-Shi Bao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9551662/zhao-shi-bao-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

475  
citations

9  
h-index

20  
g-index

20  
ext. papers

591  
ext. citations

5.1  
avg, IF

3.1  
L-index

#	Paper	IF	Citations
20	Comprehensive analysis of multi-omics data of recurrent gliomas identifies a recurrence-related signature as a novel prognostic marker. <i>American Journal of Cancer Research</i> , <b>2021</b> , 11, 1226-1246	4.4	1
19	Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. <i>Cancer Science</i> , <b>2021</b> ,	6.9	1
18	MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas <b>2021</b> , 9,		1
17	Mutation and Copy Number Alterations Analysis of KIF23 in Glioma. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 6469295	4.5	3
16	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 1	7.4	2
15	Prognostic Correlation of Autophagy-Related Gene Expression-Based Risk Signature in Patients with Glioblastoma. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 95-107	4.4	20
14	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , <b>2020</b> , 20, 187	2.6	
13	Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme. <i>Oncology Letters</i> , <b>2020</b> , 20, 1-1	2.6	1
12	Clinical and Molecular Characterization of Incidentally Discovered Lower-Grade Gliomas with Enrichment of Aerobic Respiration. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 9533-9542	4.4	3
11	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>OncImmunology</i> , <b>2019</b> , 8, e1541535	7.2	18
10	Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1756	8.4	20
9	Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas. <i>Future Oncology</i> , <b>2018</b> , 14, 545-552	3.6	0
8	Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 43-49	2.8	5
7	Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. <i>CNS Neuroscience and Therapeutics</i> , <b>2017</b> , 23, 69-75	6.8	22
6	Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas. <i>Oncotarget</i> , <b>2016</b> , 7, 45005-45014	3.3	6
5	Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions. <i>FEBS Letters</i> , <b>2015</b> , 589, 1437-43	3.8	13
4	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. <i>Oncotarget</i> , <b>2015</b> , 6, 36643-51	3.3	32

3	Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. <i>CNS Neuroscience and Therapeutics</i> , <b>2014</b> , 20, 112-8	6.8	73
2	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. <i>Genome Research</i> , <b>2014</b> , 24, 1765-73	9.7	237
1	Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. <i>CNS Neuroscience and Therapeutics</i> , <b>2013</b> , 19, 714-20	6.8	17